What is Ce3?
Ce3, Inc. operates as a full-service Contract Research Organization (CRO) specializing in early-phase oncology clinical development services tailored for the biotechnology sector. The company's core therapeutic focus is oncology, with a particular emphasis on innovative modalities such as immuno-oncology, cell therapies, and gene therapies. Established in 2005, Ce3 has consistently prioritized a deep understanding of its biotechnology clients' needs, delivering high-quality, cost-effective solutions to support their analytical, regulatory, and investor objectives. This strategic positioning within the specialized field of oncology research and development highlights Ce3's commitment to advancing novel cancer treatments.
How much funding has Ce3 raised?
Ce3 has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
What's next for Ce3?
The recent strategic investment marks a pivotal moment for Ce3, signaling strong investor confidence in its specialized oncology development services. As a company in a large-scale, late-stage funding cycle, this capital is expected to fuel further expansion of its clinical trial capabilities, potentially enhancing its service offerings in immuno-oncology and advanced cell and gene therapies. The financing will likely support operational scaling, further research initiatives, and the strengthening of strategic partnerships within the biotechnology ecosystem, positioning Ce3 for continued growth and impact in the fight against cancer.
See full Ce3 company page
